Filana Therapeutics (MEX:FLNA) General and Admin. Expense: MXN1,197.46 Mil (TTM As of Mar. 2026)


MEX:FLNA Filana Therapeutics Inc MEX:FLNA
33 GF Score
Price MXN27.00
! 2 Warning Signs
View Full Analysis

What is Filana Therapeutics General and Admin. Expense?

Filana Therapeutics MEX:FLNA 33 General and Admin. Expense is MXN1,197.46 Mil as of Mar. 2026. GuruFocus rates MEX:FLNA with a GF Score™ of 33/100. The stock has 2 warning signs investors should review.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. Filana Therapeutics's General and Admin. Expense for the three months ended in Mar. 2026 was MXN119.45 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 was MXN1,197.46 Mil.

Filana Therapeutics General and Admin. Expense Related Terms

Filana Therapeutics General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for Filana Therapeutics's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Filana Therapeutics General and Admin. Expense Chart

Filana Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
General and Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 165.24 233.72 280.65 1,497.63 1,238.79

Filana Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 223.40 758.37 145.01 174.64 119.45
MEX:FLNA
33GF Score
Filana Therapeutics Inc MEX:FLNA
General and Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Filana Therapeutics General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN1,197.46 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a General and Admin. Expense of MXN1,197.46 Mil mean?
Filana Therapeutics (MEX:FLNA) has a General and Admin. Expense of MXN1,197.46 Mil as of Mar. 2026. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Filana Therapeutics and its competitors.
Is Filana Therapeutics' General and Admin. Expense too high?
Filana Therapeutics' current General and Admin. Expense is MXN1,197.46 Mil. Overall, Filana Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Filana Therapeutics' General and Admin. Expense compare to BOLD and INKT?
Filana Therapeutics' General and Admin. Expense of MXN1,197.46 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Biotechnology company?
A good General and Admin. Expense depends on the Biotechnology industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Filana Therapeutics and its competitors. Filana Therapeutics's current General and Admin. Expense is MXN1,197.46 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Filana Therapeutics stock overvalued right now?
Filana Therapeutics (MEX:FLNA) has a current General and Admin. Expense of MXN1,197.46 Mil. The current General and Admin. Expense is MXN1,197.46 Mil. Filana Therapeutics' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For Filana Therapeutics (MEX:FLNA), the current General and Admin. Expense is MXN1,197.46 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Filana Therapeutics Business Description

Other Exchanges FLNA:USAPX91:Germany
Address 6801 N. Capital of Texas Highway, Suite 300, Building 1, Austin, TX, USA, 78731
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
33GF Score

Get the complete analysis for MEX:FLNA

General and Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN27.00
Price